Placeholder

Haiti: A Beacon of Hope Through the Rubble

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 2030. Category: .

Product Description

The pharmaceutical and biotech industry is one built upon the foundations of human fragility. It is a business of identifying physiological weaknesses and developing the medicines and products to address those faults, thus resulting in an enhanced standard of living and optimum health for the human race. It is a profession with the power to reach the farthest corners of the Earth, a brilliant beacon of hope in the dark abyss of despair. Despite the negative reporting so often associated with industry profits, over the course of the past four months, these corporations have quietly acted on the compassion that compels the industry, the aspiration to aid those in need.
On Jan. 12, 2010, tragedy struck Haiti in the form of a catastrophic 7.0 earthquake. This earthquake was the worst natural disaster to strike the Western Hemisphere in the past century, killing more than 220,000 people, injuring more than 300,000, and causing up to 4,000 amputations. Three million people, or 30% of the population, have been affected; almost 1.3 million people are living in temporary shelters in more than 400 sites in the Port-au-Prince area, while more than 600,000 have moved to outlying areas, including some 300,000 children. Total value of damages and losses from this quake are estimated at $7.86 billion, 120% of Haiti’s GDP in 2009. More than 4,300 education facilities and 50 hospitals and health centers…

Giving Back…
Catherine V. Babington. President, Abbott Fund, a philanthropic foundation established by Abbott with a mission to create a healthier global community by investing in ideas that promote science, expand access to healthcare, and strengthen communities worldwide. For more information, visit abbott-fund.org.
A.J. Kazimi. Chairman and CEO, Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription products. For more information, visit cumberlandpharma.com.
Kevin W. Sharer. Chairman, CEO, and President, Amgen Inc., a leading human therapeutics company in the biotech industry. For more information, visit amgen.com.
Robert L. Smith. President, Lilly Foundation, a philanthropic organization dedicated to improving the lives of patients and communities. For more information, visit lilly.com/responsibility/foundation.
David B. Snow Jr. Chairman and CEO, Medco Health Solutions Inc., a leading pharmacy benefit manager (PBM). For more information, visit medco.com.
Billy Tauzin. President and CEO, Pharmaceutical Research and Manufacturers of America (PhRMA), which represents the country’s leading pharmaceutical research and biotechnology companies. For more information, visit phrma.org.

FEEDBACK